Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer Licenses Cancer Compound to Puma | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pfizer Licenses Cancer Compound to Puma

To develop investigational, multi-targeted pan-HER inhibitor

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer has entered an agreement with Puma Biotechnology, Inc. to out-license development and commercialization of neratinib, an investigational oral, multi-targeted inhibitor of the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases, for the treatment of cancer.

Puma will assume responsibility for global development and commercialization of neratinib. Pfizer will be entitled to receive payments based on the achievement of certain development milestones, as well as royalty payments on neratinib sales. Further terms were not disclosed.

“Oncology is a priority for Pfizer. We are actively prioritizing our oncology portfolio, which includes deciding which compounds to develop internally and which compounds we believe may have better opportunities for development externally. This strategic approach helps ensure that people living with cancer can potentially benefit from promising drugs, regardless of where they are developed,” said Garry Nicholson, president and general manager, Pfizer Oncology.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters